CN114746096A - 使用阿伐替尼治疗嗜酸性粒细胞紊乱 - Google Patents

使用阿伐替尼治疗嗜酸性粒细胞紊乱 Download PDF

Info

Publication number
CN114746096A
CN114746096A CN202080081643.7A CN202080081643A CN114746096A CN 114746096 A CN114746096 A CN 114746096A CN 202080081643 A CN202080081643 A CN 202080081643A CN 114746096 A CN114746096 A CN 114746096A
Authority
CN
China
Prior art keywords
eosinophilic
compound
pharmaceutically acceptable
eosinophils
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080081643.7A
Other languages
English (en)
Chinese (zh)
Inventor
B·玛尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cable Chart Pharmaceutical Co
Original Assignee
Cable Chart Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cable Chart Pharmaceutical Co filed Critical Cable Chart Pharmaceutical Co
Publication of CN114746096A publication Critical patent/CN114746096A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080081643.7A 2019-10-04 2020-10-05 使用阿伐替尼治疗嗜酸性粒细胞紊乱 Pending CN114746096A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962910931P 2019-10-04 2019-10-04
US62/910,931 2019-10-04
PCT/US2020/054221 WO2021067917A1 (en) 2019-10-04 2020-10-05 Treatment of eosinophilic disorders with avapritinib

Publications (1)

Publication Number Publication Date
CN114746096A true CN114746096A (zh) 2022-07-12

Family

ID=73030210

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080081643.7A Pending CN114746096A (zh) 2019-10-04 2020-10-05 使用阿伐替尼治疗嗜酸性粒细胞紊乱

Country Status (6)

Country Link
US (1) US20240075041A1 (cg-RX-API-DMAC7.html)
EP (1) EP4041244B1 (cg-RX-API-DMAC7.html)
JP (2) JP2022551105A (cg-RX-API-DMAC7.html)
CN (1) CN114746096A (cg-RX-API-DMAC7.html)
TW (1) TW202126306A (cg-RX-API-DMAC7.html)
WO (1) WO2021067917A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX365614B (es) 2013-10-17 2019-06-07 Blueprint Medicines Corp Composiciones utiles para tratar trastornos relacionados con kit.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110003217A (zh) * 2013-10-17 2019-07-12 蓝图药品公司 可用于治疗与kit相关的病症的组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2593319T3 (es) * 2005-05-02 2016-12-07 Novartis Ag Derivados de pirimidilaminobenzamida para síndrome hipereosinofílico
JP2009515978A (ja) * 2005-11-14 2009-04-16 バイエル ヘルスケア エルエルシー Kit阻害剤に対する獲得耐性を伴う癌の治療
ES2429107T3 (es) * 2007-01-19 2013-11-13 Bayer Healthcare Llc Tratamiento de cánceres con una resistencia adquirida a los agentes inhibidores de KIT
ES2573831T3 (es) * 2011-07-27 2016-06-10 Ab Science Derivados de oxazol y tiazol como inhibidores selectivos de la proteína quinasa (C-kit)
EP2768480A1 (en) * 2011-10-21 2014-08-27 Rigel Pharmaceuticals, Inc. Method and device for administering xinafoate salt of n4-(2,2-difluoro-4h-benzo [1,4]oxazin-3-one) -6-yl]-5-fluoro-n2- [3- (methylaminocarbonylmethyleneoxy) phenyl]2,4-pyrimidinediamine
KR101652229B1 (ko) * 2012-06-07 2016-08-30 데시페라 파마슈티칼스, 엘엘씨. 증식성 질환의 치료를 위한 키나제 저해제로서 유용한 다이하이드로나프타이리딘 및 관련 화합물
CN109970745B (zh) * 2018-04-16 2020-12-08 深圳市塔吉瑞生物医药有限公司 取代的吡咯并三嗪类化合物及其药物组合物及其用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110003217A (zh) * 2013-10-17 2019-07-12 蓝图药品公司 可用于治疗与kit相关的病症的组合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANNA KOVALSZKI等: "Eosinophilia in Mast Cell Disease", IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA, vol. 34, no. 2, pages 357 - 364 *

Also Published As

Publication number Publication date
JP2022551105A (ja) 2022-12-07
EP4041244B1 (en) 2026-07-15
EP4041244A1 (en) 2022-08-17
JP2025169361A (ja) 2025-11-12
TW202126306A (zh) 2021-07-16
WO2021067917A1 (en) 2021-04-08
US20240075041A1 (en) 2024-03-07

Similar Documents

Publication Publication Date Title
US20190269671A1 (en) Method for treating tumour, pharmaceutical composition and medicinal kit
EP4385571A2 (en) Uses of a lysyl oxidase-like 2 inhibitor related applications
JP2015511632A (ja) メラノーマの治療におけるraf阻害剤およびmek阻害剤の投与
US20250017934A1 (en) New therapeutic combinations for the treatment of Progressive Fibrosing interstitial lung diseases
US20170231975A1 (en) Kinase Inhibitors
US20230181590A1 (en) New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases
JP2023058635A (ja) 過活動膀胱の治療のためのビベグロンの投薬
US20240000789A1 (en) Therapeutic combinations comprising a craf inhibitor
JP2020522560A (ja) 過活動膀胱を治療するためのビベグロンの使用
JP2025169361A (ja) アバプリチニブでの好酸球性障害の治療
CN115038447A (zh) 用于治疗癌症的组合疗法
US20190125751A1 (en) Anticancer combination therapy
TW202045180A (zh) 治療纖維化之方法
CN114945371A (zh) 肥大细胞疾病和嗜酸性粒细胞疾病的治疗
WO2010110428A1 (ja) 掻痒の予防及び/または治療剤
CN112533600A (zh) 用于治疗小细胞肺癌的喹啉衍生物
TWI668005B (zh) 逼尿肌過度活動伴收縮力降低之改善劑
CN106061505A (zh) 用于治疗癌症的含pi3k抑制剂的药物组合
TW202308631A (zh) 用於治療mpnst之化合物和組成物
KR20230061527A (ko) 염증성 장 질환을 치료하는 방법
JP2026516050A (ja) 多発性硬化症を治療するためのbtk阻害剤
KR20250145693A (ko) 미토겐 활성화 단백질 키나제(mapk) 경로 변경을 이용한 고형 종양의 치료 방법
HK40086978A (en) Therapeutic combinations comprising a craf inhibitor
JP2022547311A (ja) 骨髄線維症の治療のためのmdm2阻害剤の使用
WO2024148307A1 (en) Raf inhibitor and erk1/2 and/or shp2 inhibitor combination therapy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20220712

RJ01 Rejection of invention patent application after publication